| Sunday pm | Aging: The Failing Structural Elements |
Discussion Leader: Paul DaSilva-Jardine, Pfizer
- Professor S.W. Lambert, Erasmus University
- Chris Miller, AHP - The Discovery of the SERM, TSE424
- Lin Zhi, Ligand - Selective Androgen Receptor Modulators
- Dr. Jeff Dodge, Lilly - Peptidometric Growth Hormone Secretagogues
| Monday am | Aging: Sensory Loss |
Discussion Leader: Michael Rafferty, Parke-Davis, Warner-Lambert
- Jun Inoue, Senju Pharmaceuticals - Calpain inhibitors for cataracts and retinal degeneration
- Michael Garst, Allergan - Neuroprotective approaches to the treatment of glaucoma
- Abe Clark, Alcon Labs - Angiostatic agents for treatment of retinopathies
- Jochen Schacht, Kresge Hearing Research Center, University of Michigan Health Center
| Monday pm | Angiogenesis Inhibitors as Anti-Cancer Agents |
Discussion Leader: Rick Connell, Pfizer
- Dirk Mendel, Sugen - Small molecule inhibitors of receptor tyrosine kinases involved in angiogenesis
- Jim Hamby, Parke Davis Warner Lambert - Dual FGF/VEGF Receptor Tyrosine Kinase Inhibitors as Antiangiogenic Agents
- Paul Manley, Novartis - PTK787 / ZK222584: Discovery and Antiangiogenic Profile of a Selective VEGFR-2 Kinase Inhibitor
- Steve Davidsen, Abbott - Discovery and anti-tumor properties of selective MMP inhibitors
| Tuesday am | Can we really predict human pharmacokinetics? |
Discussion Leader: Cosette Serabjit-Singh, Glaxo Wellcome
- Scott Obach, Pfizer - The Prediction of Human Pharmacokinetics: An Overview of Recent Research
- Brian Houston, U. Manchester - In vitro drug metabolizing systems for determining intrinsic clearance and predicting human drug clearance
- Richard Kim, Vanderbilt - Drug Uptake and Efflux Transporters and Drug Clearance Predictions
- Lawrence Yu, FDA - An Integrated Approach to Predicting Human Oral Bioavailability
| Tuesday pm | Antiviral Therapy: New Approaches in the Hot Zone |
Discussion Leader: Kazumi Shiosaki, Millenium Pharmaceuticals
- Jeff Hale, Merck - CCR5 antagonists
- T.J. Nitz, Viropharma - RSV
- Clarence Maring, Abbott - Neuraminidase
- David Myles, Chiron
| Wednesday am | Small Molecule Ligands for G-Protein Coupled Receptors |
Discussion Leader: Lihu Yang, Merck
- Prof. Thue W. Schwartz, University of Copenhagen - Active states of 7TM receptors - metal-ion site engineering and G-protein fusions
- Dr. Lihu Yang, Merck - Somatostatin (sst2) agonists: from peptidyl privileged structures to small molecules.
- Dr. Eugene Trybulski, AHP - The Discovery of Selective Non-Peptide Agonists and Antagonists of the Vasopressin Receptors.
- Dr. Hiroshi Kayakiri, Fujisawa - The First Selective Non-peptide Bradykinin B2 Receptor Agonists and Antagonists
| Wednesday Afternoon | Poster Session |
Organizer: Peter Bernstein, Astra-Zeneca
| Wednesday pm | Advances in Psychotherapeutics |
Discussion Leader: Philip Hipskind, Lilly
- Chon Chen, NBI/Jannsen - Discovery Of Small Molecules As Potent Corticotropin-Releasing Factor-1 Receptor Antagonists
- Varghese John, Elan/Athena - Inhibitors of APP Processing
- James Monn, Lilly - Metabotropic Glutamate Receptors as Novel Targets for the Treatment of Psychiatric Disorders
- Chris Swain, Merck -
| Thursday am | Special Topics |
Discussion Leader: Samuel Chackalamannil, Schering
- Alan Stobie, Pfizer - The Discovery of UK's 240,455 and 315,716
- Jonathan Houze, Tularik - T900607: Synthesis and SAR studies of a second-generation irreversible binder of beta-tubilin
- Gang Liu, Abbott - Discovery of novel p-arylthio cinnamides as water soluble and orally bioavailable antagonists of LFA/ICAM-1 interaction
- John Clader, Schering-Plough - Discovery of Potent and Highly Selective Muscarinic M2 Antagonists: A Promising New Approach to the Treatment of Alzheimer's Disease
| Thursday Afternoon | Poster session |
Organizer: Peter Bernstein, Astra-Zeneca
| Thursday pm | Knowledge Management |
- Larry Prusak, IBM Institute for Knowledge Management
|
